The use of dihydrofolate reductase as a signal for scheduling optimal treatment with antileukemic agents.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D007093:Imidazoles / Q000008:administration & dosage; D007939:Leukemia L1210 / Q000188:drug therapy / Q000201:enzymology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism*
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D007093:Imidazoles; D009607:Nitrosourea Compounds; D003520:Cyclophosphamide; D013762:Tetrahydrofolate Dehydrogenase